The Impact of Haemophilus Influenzae and Streptococcus Pneumoniae Vaccination in Bacterial Meningitis in a Pediatric Referral Hospital in Mexico

Abstract

Objective This study aimed to compare the epidemiology of bacterial meningitis (BM) before and after vaccination, and identify possible risk factors associated with mortality.

Methods The medical and microbiologic records of children (1 month–18 years) with a discharge diagnosis of BM in a third level children's hospital in Mexico from 1990 to 2018 were reviewed. The epidemiology, pathogens, and outcomes were compared before and after introducing Haemophilus influenzae type b (Hib) and pneumococcal conjugate vaccines to the Mexican immunization schedule. Risk factors associated with mortality were determined.

Results In the 28-year period, 226 cases with BM were included 55.8% (1990–1999), 27.4% (2000–2008), and 16.8% (2009–2018) (p = 0.0001). The most frequent pathogen was Hib, documented in 39% of cases. There was a reduction in neurological complications after introducing the Hib conjugate vaccine (59 vs. 39%; p = 0.003) and sequelae after the Streptococcus pneumoniae conjugate vaccine (43 vs. 35%; p = 0.05). Independent risk factors associated with mortality were coma (odds ratio [OR]: 15 [2.9–78]), intracerebral bleeding (OR: 3.5 [1.4–12]), and pneumococcal meningitis (OR: 9.4 [2.2–39]).

Conclusion Since the introduction of Hib and pneumococcal conjugate vaccines to the national immunization schedule, there was a reduction in BM cases, mainly associated with the Hib vaccine, with the consequent reduction of neurological complications and sequelae.

Keywords

Haemophilus influenzae - Streptococcus pneumoniae - vaccination - meningitis - epidemiology

Publikationsverlauf

Eingereicht: 05. Dezember 2020

Angenommen: 11. April 2021

Artikel online veröffentlicht:
26. Juni 2021

• References

• 1 Husain E, Chawla R, Dobson S, Dele Davies H. Paediatric Investigators Collaborative Network on Infections in Canada. Epidemiology and outcome of bacterial meningitis in Canadian children: 1998-1999. Clin Invest Med 2006; 29 (03) 131-135
• 2 Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2015; 2016 (09) CD004405
• 3 Thigpen MC, Whitney CG, Messonnier NE. et al; Emerging Infections Programs Network. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011; 364 (21) 2016-2025
• 4 Cripps AW, Leach AJ, Lehmann D. Pneumococcal vaccination in developing countries. Lancet 2006; 368 (9536): 644
• 5 Clemens J, Jodar L. Hib vaccines for all the world's children?. Lancet 2005; 366 (9480): 101-103
• 6 McIntyre PB, O'Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet 2012; 380 (9854): 1703-1711
• 7 Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis 2014; 14 (09) 813-819
• 8 Oordt-Speets AM, Bolijn R, van Hoorn RC, Bhavsar A, Kyaw MH. Global etiology of bacterial meningitis: a systematic review and meta-analysis. PLoS One 2018; 13 (06) e0198772
• 9 Gómez de León Cruces P, Díaz García J, Santos JI. Effect of the DTwP Haemophilus influenzae b conjugate vaccination in Mexico (1999-2007). Arch Med Res 2010; 41 (04) 281-287
• 10 Daniels N, Valencia-Mendoza A, Gelpi A, Avila MH, Bertozzi S. The art of public health: pneumococcal vaccine coverage in Mexico. Lancet 2010; 375 (9709): 114-115
• 11 Wasserman M, Wilson M, McDade C. et al. Estimating the clinical and economic impact of maintaining use of 13-valent pneumococcal conjugate vaccine (PCV13) in Mexico. Open Forum Infect Dis 2017; 4 (Suppl. 01) S463-S463
• 12 WHO. Immunization country profile. Published 2016. Accessed January 4, 2021. Accessed 2016 at: http://apps.who.int/immunization_monitoring/globalsummary/estimates?c=KEN%0Ahttp://apps.who.int/immunization_monitoring/globalsummary/countries?countrycriteria%255Bcountry%255D%255B%255D=GRC&commit=OK%250Ahttp://apps.who.int/immunization_monitoring/glob
• 13 Gómez-Barreto D, Espinosa-Monteros LE, López-Enríquez C, Jiménez-Rojas V, Rodríguez-Suárez R. Enfermedad neumocócica invasora en un hospital pediátrico de tercer nivel en la Ciudad de México: características epidemiológicas y factores de riesgo asociados con mortalidad. Salud Publica Mex 2010; 52 (05) 391-397
• 14 Wasserman M, Palacios MG, Grajales AG. et al. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother 2019; 15 (03) 560-569
• 15 Richardson V, Sánchez-Uribe E, Esparza-Aguilar M, Esteves-Jaramillo A, Suárez-Idueta L. Contribution of Mexico's universal immunization program to the fourth millennium development goal. Rev Panam Salud Publica 2014; 35 (04) 248-255
• 16 Franco-Paredes C, Lammoglia L, Hernández I, Santos-Preciado JI. Epidemiology and outcomes of bacterial meningitis in Mexican children: 10-year experience (1993-2003). Int J Infect Dis 2008; 12 (04) 380-386
• 17 Quezada FO. Instituto Nacional de Pediatría. Agenda estadística. Accessed January 3, 2021 at: https://www.pediatria.gob.mx/
• 18 Direccion general de informacion en salud. Documentos, Archivo, Secretaría de Salud, Gobierno, and gob.mx. Accessed January 6, 2021 at: https://www.gob.mx/salud/es/archivo/documentos
• 19 van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010; 362 (02) 146-154
• 20 WHO – recommended standards for surveillance of selected vaccine-preventable diseases. Vaccines Biol. Accessed 2021 at: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/standards/en/
• 21 Curtis S, Stobart K, Vandermeer B, Simel DL, Klassen T. Clinical features suggestive of meningitis in children: a systematic review of prospective data. Pediatrics 2010; 126 (05) 952-960
• 22 Kaplan SL, Mason Jr EO, Wald ER. et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113 (3 Pt 1): 443-449
• 23 Davis S, Feikin D, Johnson HL. The effect of Haemophilus influenzae type B and pneumococcal conjugate vaccines on childhood meningitis mortality: a systematic review. BMC Public Health 2013; 13 (03, Suppl 3): S21
• 24 de Salud S. Anuarios de Morbilidad 1984–2019. Accessed September 19, 2020 at: https://www.gob.mx/salud/acciones-y-programas/anuarios-de-morbilidad-1984-2019
• 25 Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13 (02) 302-317
• 26 DeAntonio R, Amador S, Bunge EM. et al. Vaccination herd effect experience in Latin America: a systematic literature review. Hum Vaccin Immunother 2019; 15 (01) 49-71
• 27 Tuyama M, Corrêa-Antônio J, Schlackman J. et al. Invasive Haemophilus influenzae disease in the vaccine era in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 2017; 112 (03) 196-202
• 28 Danovaro-Holliday MC, Garcia S, de Quadros C, Tambini G, Andrus JK. Progress in vaccination against Haemophilus influenzae type b in the Americas. PLoS Med 2008; 5 (04) e87
• 29 Koelman DLH, Brouwer MC, van de Beek D. Resurgence of pneumococcal meningitis in Europe and Northern America. Clin Microbiol Infect 2020; 26 (02) 199-204
• 30 Carnalla-Barajas MN, Soto-Noguerón A, Sánchez-Alemán MA, Solórzano-Santos F, Velazquez-Meza ME, Echániz-Aviles G. Grupo SIREVA-Mexico. Changing trends in serotypes of S. pneumoniae isolates causing invasive and non-invasive diseases in unvaccinated population in Mexico (2000-2014). Int J Infect Dis 2017; 58: 1-7
• 31 Oligbu G, Collins S, Djennad A. et al. Effect of pneumococcal conjugate vaccines on pneumococcal meningitis, England and Wales, July 1, 2000-June 30, 2016. Emerg Infect Dis 2019; 25 (09) 1708-1718
• 32 Ali M, Chang BA, Johnson KW, Morris SK. Incidence and aetiology of bacterial meningitis among children aged 1-59 months in South Asia: systematic review and meta-analysis. Vaccine 2018; 36 (39) 5846-5857
• 33 Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML. Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines 2014; 2 (06) 155-158
• 34 Vespa Presa J, Abalos MG, Sini de Almeida R, Cane A. Epidemiological burden of meningococcal disease in Latin America: a systematic literature review. Int J Infect Dis 2019; 85: 37-48
• 35 Sáfadi MAP, Cintra OAL. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurol Res 2010; 32 (03) 263-271
• 36 Chacon Cruz E, Alvelais Palacios JA, Lopatynsky Reyes EZ, Rodriguez Valencia JA, Volker Soberanes ML. Meningococcal disease in children: eleven years of active surveillance in a mexican hospital and the need for vaccination in the Tijuana region. J Infect Dis Treat 2017; 3 (01) 1-4
• 37 Almeida-González L, Franco-Paredes C, Pérez LF, Santos-Preciado JI. Enfermedad por meningococo, Neisseria meningitidis: perspectiva epidemiológica, clínica y preventiva. Salud Publica Mex 2004; 46 (05) 438-450
• 38 Chacon-Cruz E, Roberts C, Rivas-Landeros RM, Lopatynsky-Reyes EZ, Almada-Salazar LA, Alvelais-Palacios JA. Pediatric meningitis due to Neisseria meningitidis, Streptococcus pneumoniae and Group B Streptococcus in Tijuana, Mexico: active/prospective surveillance, 2005-2018. Ther Adv Infect Dis 2019; 6: 2049936119832274
• 39 Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10 (05) 317-328
• 40 Golding N, Burstein R, Longbottom J. et al. Mapping under-5 and neonatal mortality in Africa, 2000-15: a baseline analysis for the sustainable development goals. Lancet 2017; 390 (10108): 2171-2182